David Hawman

Dr. David Hawman

Laboratory of Virology, Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT 59840, USA
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2023 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
David HawmanDavid Hawman
David Hawman
HFHeinz Feldmann
Heinz Feldmann

5 August 2020 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
JEJesse H. Erasmus
Jesse H. Erasmus
AKAmit P. Khandhar
Amit P. Khandhar
MOMegan A. O’connor
Megan A. O’connor
AWAlexandra C. Walls
Alexandra C. Walls
EHEmily A. Hemann
Emily A. Hemann
Deborah FullerDeborah Fuller
Deborah Fuller
Replicating RNA vaccine delivered by lipid inorganic nanoparticles induces neutralizing antibody and T cells against SARS-CoV-2 in mice and macaques.

29 October 2018 in F1000Research
Verified
Journal Article
Open access
PDF file
David HawmanDavid Hawman
David Hawman
HFHeinz Feldmann
Heinz Feldmann
Crimean-Congo hemorrhagic fever virus (CCHFV) is a widely distributed hemorrhagic fever virus and the cause of hemorrhagic disease in Africa, Southern and Eastern Europe, the Middle East, India and Asia. Recent emergence of CCHFV into Spain indicates that the geographic range of this virus is expanding and the presence of its tick vector in several countries without reported disease suggest that CCHFV will continue to spread. Research into CCHFV was historically limited by a lack of suitable animal models and tools to study viral pathogenesis. However, in the past few years the toolset for studying CCHFV has expanded with small animal and non-human primate models for CCHFV being developed along with a reverse genetics system that allows for investigation of viral determinants of disease. These tools have been utilized to understand how CCHFV antagonizes host restriction factors and to develop novel vaccine candidates that may help limit the substantial morbidity and mortality in humans caused by CCHFV.

18 February 2021 in Viruses
Verified
Journal Article
Open access
PDF file
SLShanna Leventhal
Shanna Leventhal
DWDrew Wilson
Drew Wilson
HFHeinz Feldmann
Heinz Feldmann
David HawmanDavid Hawman
David Hawman
In 2016, the Bunyavirales order was established by the International Committee on Taxonomy of Viruses (ICTV) to incorporate the increasing number of related viruses across 13 viral families. While diverse, four of the families (Peribunyaviridae, Nairoviridae, Hantaviridae, and Phenuiviridae) contain known human pathogens and share a similar tri-segmented, negative-sense RNA genomic organization. In addition to the nucleoprotein and envelope glycoproteins encoded by the small and medium segments, respectively, many of the viruses in these families also encode for non-structural (NS) NSs and NSm proteins. The NSs of Phenuiviridae is the most extensively studied as a host interferon antagonist, functioning through a variety of mechanisms seen throughout the other three families. In addition, functions impacting cellular apoptosis, chromatin organization, and transcriptional activities, to name a few, are possessed by NSs across the families. Peribunyaviridae, Nairoviridae, and Phenuiviridae also encode an NSm, although less extensively studied than NSs, that has roles in antagonizing immune responses, promoting viral assembly and infectivity, and even maintenance of infection in host mosquito vectors. Overall, the similar and divergent roles of NS proteins of these human pathogenic Bunyavirales are of particular interest in understanding disease progression, viral pathogenesis, and developing strategies for interventions and treatments.

27 July 2022 in EBioMedicine
Verified
Journal Article
Open access
SLShanna S. Leventhal
Shanna S. Leventhal
KMKimberly Meade-White
Kimberly Meade-White
DRDeepashri Rao
Deepashri Rao
EHElaine Haddock
Elaine Haddock
JLJacqueline Leung
Jacqueline Leung
David HawmanDavid Hawman
David Hawman
Crimean-Congo hemorrhagic fever virus is the cause of a severe hemorrhagic fever with cases reported throughout a wide-geographic region. Spread by the bite of infected ticks, contact with infected livestock or in the health care setting, disease begins as a non-specific febrile illness that can rapidly progress to hemorrhagic manifestations. Currently, there are no approved vaccines and antivirals such as ribavirin have unclear efficacy. Thus treatment is mostly limited to supportive care. In this report we evaluated an alphavirus-based replicon RNA vaccine expressing either the CCHFV nucleoprotein or glycoprotein precursor in a stringent, heterologous lethal challenge mouse model. Vaccination with the RNA expressing the nucleoprotein alone could confer complete protection against clinical disease, but vaccination with a combination of both the nucleoprotein and glycoprotein precursor afforded robust protection against disease and viral replication. Protection from lethal challenge required as little as a single immunization with 100ng of RNA. Unexpectedly, analysis of the immune responses elicited by the vaccine components showed that vaccination resulted in antibodies against the internal viral nucleoprotein and cellular immunity against the virion-exposed glycoproteins. Cumulatively this vaccine conferred robust protection against Crimean-Congo hemorrhagic fever virus and supports continued development of this vaccine candidate. This research was supported by the Intramural Research Program of the NIAID/NIH and HDT Bio.

28 March 2024 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
VMVanessa Monteil
Vanessa Monteil
SWShane C. Wright
Shane C. Wright
MDMatheus Dyczynski
Matheus Dyczynski
MKMax J. Kellner
Max J. Kellner
SASofia Appelberg
Sofia Appelberg
AMAli Mirazimi
Ali Mirazimi
Climate change and population densities accelerated transmission of highly pathogenic viruses to humans, including the Crimean–Congo haemorrhagic fever virus (CCHFV). Here we report that the Low Density Lipoprotein Receptor (LDLR) is a critical receptor for CCHFV cell entry, playing a vital role in CCHFV infection in cell culture and blood vessel organoids. The interaction between CCHFV and LDLR is highly specific, with other members of the LDLR protein family failing to bind to or neutralize the virus. Biosensor experiments demonstrate that LDLR specifically binds the surface glycoproteins of CCHFV. Importantly, mice lacking LDLR exhibit a delay in CCHFV-induced disease. Furthermore, we identified the presence of Apolipoprotein E (ApoE) on CCHFV particles. Our findings highlight the essential role of LDLR in CCHFV infection, irrespective of ApoE presence, when the virus is produced in tick cells. This discovery holds profound implications for the development of future therapies against CCHFV.